Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 29 h ago

Neurogene Inc.: Samsara BioCapital, L.P. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Samsara BioCapital, L.P. filed an amended Schedule 13G with the SEC (accession 0001699737-26-000026) updating its beneficial ownership stake in Neurogene Inc. The filing, submitted under the 13G regime used by passive and institutional investors, revises the firm's previously reported position in the gene therapy developer. The amendment signals a change in Samsara's reported holdings, though the filing itself does not indicate whether the shift reflects active buying or selling. Investors should watch for the specific share count and percentage disclosed in the amendment, as 13G updates can precede larger position changes by institutional holders.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Samsara BioCapital, L.P., Neurogene Inc.